Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

81. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome

Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

82. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care

Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

83. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome (Abstract)

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome The intestinal permeability is increased in patients with diarrhoea-predominant irritable bowel syndrome (D-IBS).To determine the possible efficacy of lactic acid bacteria on the increased intestinal permeability in D-IBS.Treatment was employed for 4 weeks in a randomized single blind placebo controlled study with 30 D-IBS patients. Patients were (...) given either probiotic fermented milk (Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus and Bifidobacterium Longum) or milk beverage containing no bacteria. The clinical symptoms were scored and intestinal permeability was measured by a triple sugar test before and after treatment.Small bowel permeability was measured as the ratio of lactulose and mannitol recovery and colonic permeability was measured as the total mass of sucralose excretion (mg). After probiotics

2008 EvidenceUpdates Controlled trial quality: uncertain

84. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome (Abstract)

Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome In models of irritable bowel syndrome (IBS), asimadoline, a kappa-opioid agonist, improves pain and abnormal bowel function.To evaluate the effects of three doses of asimadoline and placebo in subjects with IBS through a double-blind, randomized, placebo-controlled trial.Patients were randomly assigned to receive asimadoline 0.15, 0.5, 1.0 mg or placebo BID for 12 weeks. The primary efficacy measure

2008 EvidenceUpdates Controlled trial quality: predicted high

85. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents (Abstract)

Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents To determine the efficacy of amitriptyline (AMI) in treating irritable bowel syndrome (IBS) in adolescents.Adolescents 12 to 18 years with newly diagnosed IBS were surveyed with a symptom checklist, pain rating scale, visual analog scale, and IBS quality of life (QOL) questionnaire. Subjects were randomized in a double-blinded fashion to receive AMI or placebo, and again completed (...) , .039, and .004).AMI significantly improves overall QOL in adolescents with IBS and should be a therapeutic option for adolescents with this disorder.

2008 EvidenceUpdates Controlled trial quality: predicted high

86. Effectiveness of probiotics in the treatment of irritable bowel syndrome Full Text available with Trip Pro

Effectiveness of probiotics in the treatment of irritable bowel syndrome Recently, the use of tegaserod and alosetron -- drugs approved for the treatment of irritable bowel syndrome (IBS) -- has been restricted because of adverse events. This has resulted in a need for additional modalities for the treatment of IBS. Our objective was to determine the effectiveness of probiotics in the global relief of symptoms associated with IBS and in the improvement of flatulence, abdominal pain, transit (...) time, and bacterial counts. Using the MEDLINE database from 1966-October 2007 and manually searching article references for relevant articles and abstracts, we identified 14 blinded, placebo-controlled clinical trials of the effectiveness of probiotics in the treatment of IBS. Of 11 studies in which overall symptom relief was assessed, seven indicated a significant improvement with probiotics versus placebo. Five of eight investigations of abdominal pain and distention revealed a benefit

2008 EvidenceUpdates

87. Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. (Abstract)

Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Between 4% and 25% of school-age children complain of recurrent abdominal pain (RAP) of sufficient severity to interfere with daily activities. For the majority of such children, no organic cause for their pain can be found on physical examination or investigation. Although most children are managed by reassurance and simple measures, a large range of psychosocial interventions (...) filters.Any study in which the majority of participants were school-age children fulfilling standard criteria for RAP (Apley or the Rome II criteria for functional gastrointestinal diseases) , randomly allocated to any psychosocial treatment compared to standard care or waiting list, were selected.References identified by the searches were independently screened against the inclusion criteria by two reviewers. Data were extracted and analysed using RevMan 4.2.10.Six randomised trials (including a total

2008 Cochrane

88. Irritable bowel syndrome in adults: diagnosis and management

and evidence used to update these recommendations. Irritable bowel syndrome (IBS) is a chronic, relapsing and often life-long disorder. It is characterised by the presence of abdominal pain or discomfort, which may be associated with defaecation and/or accompanied by a change in bowel habit. Symptoms may include disordered defaecation (constipation or diarrhoea or both) and abdominal distension, usually referred to as bloating. Symptoms sometimes overlap with other gastrointestinal disorders such as non (...) Initial assessment Initial assessment 1.1.1.1 Healthcare professionals should consider assessment for IBS if the person reports having had any of the following symptoms for at least 6 months: A Abdominal pain or discomfort B Bloating C Change in bowel habit. [2008] [2008] Irritable bowel syndrome in adults: diagnosis and management (CG61) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 10 of 221.1.1.2 All people

2008 National Institute for Health and Clinical Excellence - Clinical Guidelines

89. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. Full Text available with Trip Pro

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. To investigate whether placebo effects can experimentally be separated into the response to three components-assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient-practitioner relationship-and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude

2008 BMJ Controlled trial quality: predicted high

90. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized controlled trials

Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

91. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

92. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

93. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

16 years or over, with irritable bowel syndrome (IBS) not related to organic disease and diagnosed according to specific criteria (i.e. Manning, Kruis score, Rome I, II or III), were eligible for inclusion. Eligible studies were required to include treatment duration of at least one week and at least one week follow-up. Studies were also required to report a global assessment of cure or improvement of symptoms, or cure or improvement of abdominal pain, as reported by the patient or health (...) Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Ford A C, Talley N J, Spiegel B M, Foxx-Orenstein A E, Schiller L, Quigley E M, Moayyedi P CRD

2008 DARE.

94. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Full Text available with Trip Pro

that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA 2008; 300(15): 1793-1805 PubMedID DOI Other publications of related interest Bursey F. Review: combinations of clinical findings had moderate sensitivity and specificity for diagnosing the irritable bowel syndrome. APC Journal Club 2009;150:13 Indexing Status Subject indexing assigned by NLM MeSH Abdominal Pain /etiology; Diagnosis, Differential; Diarrhea /etiology; Humans; Irritable Bowel Syndrome /diagnosis (...) Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Ford A C, Talley N J, Velhuyzen van Zenten

2008 DARE.

95. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials

that there was no statistically significant evidence that selective serotonin reuptake inhibitors (SSRIs) improved abdominal pain, bloating or irritable bowel syndrome (IBS) symptoms, although there was a trend for improvement in abdominal pain. In view of methodological limitations in the review, in particular the failure to adequately address heterogeneity, the conclusions may not be reliable. Authors' objectives To determine the efficacy of selective serotonin reuptake inhibitors (SSRIs) for irritable bowel syndrome (IBS (...) Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Rahimi R, Nikfar S, Abdollahi M CRD summary The authors stated

2008 DARE.

96. The relationship between somatisation and outcome in patients with severe irritable bowel syndrome

The relationship between somatisation and outcome in patients with severe irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

97. Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome

Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

98. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting (Abstract)

to placebo. Renzapride was well tolerated at all doses.This study confirms the gastrointestinal prokinetic effects of renzparide. The data also suggested a potentially beneficial effect on abdominal pain/discomfort in women with constipation-predominant irritable bowel syndrome. (...) Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting Relatively few pharmacological treatment options are available for treating patients with irritable bowel syndrome. New and effective medicines are urgently required.To identify an appropriate dosage of renzapride (a 5-HT(4) receptor full agonist/5-HT(3) receptor antagonist) to treat abdominal pain/discomfort

2008 EvidenceUpdates Controlled trial quality: predicted high

99. Hypnotherapy for Children With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Controlled Trial. (Abstract)

Hypnotherapy for Children With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Controlled Trial. BACKGROUND & AIMS: Functional abdominal pain (FAP) and irritable bowel syndrome (IBS) are highly prevalent in childhood. A substantial proportion of patients continues to experience long-lasting symptoms. Gut-directed hypnotherapy (HT) has been shown to be highly effective in the treatment of adult IBS patients. We undertook a randomized controlled trial and compared clinical (...) effectiveness of HT with standard medical therapy (SMT) in children with FAP or IBS. METHODS: Fifty-three pediatric patients, age 8-18 years, with FAP (n = 31) or IBS (n = 22), were randomized to either HT or SMT. Hypnotherapy consisted of 6 sessions over a 3-month period. Patients in the SMT group received standard medical care and 6 sessions of supportive therapy. Pain intensity, pain frequency, and associated symptoms were scored in weekly standardized abdominal pain diaries at baseline, during therapy

2007 EvidenceUpdates Controlled trial quality: uncertain

100. Hypnotherapy for treatment of irritable bowel syndrome. Full Text available with Trip Pro

Hypnotherapy for treatment of irritable bowel syndrome. Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder of unknown aetiology. Current pharmacological treatments have limited value. Hypnotherapy has been reported to have beneficial effects for IBS symptoms.To evaluate the efficacy of hypnotherapy for the treatment of irritable bowel syndrome.Published and unpublished randomised clinical trials and quasi-randomised clinical trials were identified through structured (...) for the treatment of irritable bowel syndrome with no treatment or another therapeutic intervention.All studies were evaluated for eligibility for inclusion. Included studies were assessed for quality and data were extracted independently by four authors. The primary outcome measure of interest was the overall bowel symptom severity score which combines abdominal pain, diarrhoea or constipation and bloating. Secondary outcomes included abdominal pain, diarrhoea, constipation, bloating, quality of life

2007 Cochrane